Key result
Ultrathin Tetrilimus everolimus-eluting stents show an 8.6% 3-year TLF rate in a real-world registry.
Observational (n=594)
The ultrathin strut biodegradable polymer-coated everolimus-eluting stent demonstrated sustained safety and effectiveness with an 8.6% target lesion failure rate and no definite stent thrombosis at 3 years.
The registry reports 3-year safety and clinical performance of the ultrathin strut (60 μm) biodegradable polymer-coated Tetrilimus, an everolimus-eluting stent (EES) (Sahajanand Medical Technologies Limited, India), in 'real-world' patients with coronary artery disease. A total of 815 Tetrilimus EES were implanted in 735 lesions in 594 patients. At 3-year follow-up, primary endpoint (target lesion failure, TLF) was reported in 8.6 % patients, including 2.6 % cardiac deaths, 3.5 % myocardial infarction and 2.6 % target lesion revascularization. At three-year, no cases of definite stent thrombosis were reported. The final three-year results of PERFORM-EVER registry endorse the continuous safety and effectiveness Tetrilimus EES.
No takes yet. Share an insight, caveat, or question.
Kasturi et al. (2023) conducted an observational in coronary artery disease (n=594). Tetrilimus everolimus-eluting stent (EES) was evaluated on target lesion failure (TLF). The ultrathin biodegradable polymer-coated Tetrilimus everolimus-eluting stent demonstrated a 3-year target lesion failure rate of 8.6% in a real-world registry.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: